Peptide origin / Partial sequence of human gastric protein BPC, isolated from gastric juice Molecular weight / Approximately 1,419 Da (15 amino acids) Common off-label oral dose / 250 to 500 mcg twice daily, taken on an empty stomach Common off-label subcutaneous dose / 200 to 300 mcg once or twice daily near the affected area or abdominally Evidence level / Preclinical only (GRADE: very low certainty for human GI healing) Key preclinical finding / Accelerated gastric ulcer healing in rats within 24 to 72 hours across multiple models Route preference for GI targets / Oral administration, based on topical mucosal contact rationale Safety profile in humans / Largely unknown
We're going to examine all of this in more detail shortly, but first
GHS-R1a antagonists have been demonstrated to attenuate alcohol consumption, reward and reinforcement, but to be an effective therapeutic for alcohol dependence it should prevent relapse
Address any specific concerns you have with your provider
Glycemic monitoring should increase to at least weekly fingerstick or continuous glucose monitoring (CGM) review during taper, because removing the GLP-1 agonist effect will raise postprandial glucose in T2D patients
Industry Perspectives and Expert Commentary Industry commentators have broadly echoed FDAs enforcement stance
:format(webp))
